Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline
| Autor: | James J. Chamberlain, Jennifer M. Trujillo, Jay H. Shubrook, Kacie Doyle-Delgado, Neil Skolnik |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Blood Glucose
medicine.medical_specialty MEDLINE Type 2 diabetes 01 natural sciences Glucagon-Like Peptide-1 Receptor 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Diabetes mellitus Internal Medicine medicine Humans Hypoglycemic Agents Insulin 030212 general & internal medicine 0101 mathematics Glycemic Glycated Hemoglobin American diabetes association business.industry Public health 010102 general mathematics General Medicine Guideline medicine.disease Metformin Diabetes Mellitus Type 2 Family medicine Drug Therapy Combination business |
| Zdroj: | Annals of Internal Medicine. 173:813-821 |
| ISSN: | 1539-3704 0003-4819 |
| DOI: | 10.7326/m20-2470 |
| Popis: | Description The American Diabetes Association (ADA) updates the Standards of Medical Care in Diabetes annually to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of diabetes. Methods To develop the 2020 Standards, the ADA Professional Practice Committee, comprising physicians, adult and pediatric endocrinologists, diabetes educators, registered dietitians, epidemiologists, pharmacists, and public health experts, continuously searched MEDLINE (English language only) from 15 October 2018 through August-September 2019 for pertinent studies, including high-quality trials that addressed pharmacologic management of type 2 diabetes. The committee selected and reviewed the studies, developed the recommendations, and solicited feedback from the larger clinical community. Recommendations This synopsis focuses on guidance relating to the pharmacologic treatment of adults with type 2 diabetes. Recommendations address oral and noninsulin injectable therapies, insulin treatment, and combination injectable therapies. Results of recent large trials with cardiovascular and renal outcomes are emphasized. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|